Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Teva Pharmaceutical Industries Ltd (TEVA) NYSE

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 34,479,552
  • Shares Outstanding, K 1,015,000
  • Annual Sales, $ 19,652 M
  • Annual Income, $ 1,588 M
  • 36-Month Beta 0.65
  • Price/Sales 1.70
  • Price/Book 1.03

Price Performance

See More
Period Period Low Period High Performance
1-Month
33.56 +1.61%
on 01/11/17
38.31 -10.99%
on 01/04/17
-2.41 (-6.60%)
since 12/16/16
3-Month
33.56 +1.61%
on 01/11/17
44.42 -23.23%
on 10/25/16
-9.16 (-21.17%)
since 10/18/16
52-Week
33.56 +1.61%
on 01/11/17
64.31 -46.98%
on 01/25/16
-28.42 (-45.46%)
since 01/15/16

Most Recent Stories

More News
Teva Receives FDA Approval for VANTRELA(TM) ER (Hydrocodone Bitartrate) Extended-Release Tablets [CII] Formulated with Proprietary Abuse Deterrence Technology

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the U.S. Food and Drug Administration (FDA) approved VANTRELA(TM) ER (hydrocodone bitartrate) extended-release tablets...

Lilly-Incyte Rheumatoid Arthritis Drug PDUFA Date Extended

Eli Lilly and Company (LLY) and Incyte Corporation (INCY) announced that the FDA has extended the time to review the company's NDA for baricitinib for the treatment of rheumatoid arthritis (RA).

Lilly Wins Appeal Against Teva in Alimta Patent Lawsuit

Eli Lilly and Company (LLY) announced that it has received a favorable ruling in a lawsuit against generic drugmaker Teva Pharmaceutical Industries Limited (TEVA) related to the infringement of a vitamin...

Pharma Stock Roundup: Trump Targets Pharma Again, Merck Up on Keytruda News

The sector was once again slammed by president-elect Donald Trump's comments this week regarding drug pricing.

New Strong Sell Stocks for January 11th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Wednesday

Merrimack (MACK) Sells Onivyde Rights to Ipsen for $1B

Merrimack Pharmaceuticals, Inc. (MACK) announced that it has entered into an agreement with Ipsen for $1.0 billion for Onivyde.

Stock Market News for January 09, 2017

Benchmarks posted modest gains on Friday following a solid December U.S. jobs report

Impax (IPXL) Applies for Generic Aubagio; Sanofi Files Lawsuit

Impax Laboratories, Inc. (IPXL) announced that it has filed an Abbreviated New Drug application (ANDA) with the FDA for a generic version of Sanofi's Aubagio (teriflunomide) tablets, 14 mg.

Teva Falls on Disappointing 2017 Sales & Earnings Guidance

Teva Pharmaceutical Industries Ltd. (TEVA) provided a weaker-than-expected sales and earnings guidance for 2017, seeing that its blockbuster multiple sclerosis drug, Copaxone, is reeling under competitive...

Teva Announces Completion of Sale of UK and Ireland Actavis Assets and Operations Following European Commission Approval

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the completion of the sale of the majority of the assets and operations of Actavis Generics in the UK and Ireland...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More

Business Summary

TEVA Pharmaceuticals USA, the business is to develop, manufacture, and market generic pharmaceuticals. Teva USA sells its products to chains, wholesalers, distributors, hospitals, managed care entities, and government agencies. The company markets a variety of dosage forms, including both extended...

See More

Support & Resistance

2nd Resistance Point 34.48
1st Resistance Point 34.29
Last Price 34.10
1st Support Level 33.82
2nd Support Level 33.54

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.